Mesoblast Limited vs TAL Education Group American Depositary Shares — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while TAL Education Group American Depositary Shares trades at $12.49 (market cap $6.93B). The key difference: TAL Education Group American Depositary Shares is far larger — about 4× Mesoblast Limited's market cap, and TAL Education Group American Depositary Shares is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and TAL Education Group American Depositary Shares for 0 Days on average.
| MESO | TAL | |
|---|---|---|
Market Cap | $1.75B | $6.93B |
Volume | 239,027 | 2,470,140 |
Sector | Health | Consumer Staples |
52-Week High | $20.96 | $12.91 |
52-Week Low | $13.19 | $8.95 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $1.83B | $4.46B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →TAL Education Group provides smart learning solutions in China. Its offerings combine teaching content, technology, and learning services through various online and offline formats.
Read more on TAL →